Filing Scope and Business Context
The provided filing is Blade Air Mobility, Inc.’s Form 10-K for the fiscal year ended December 31, 2023, filed March 12, 2024. The request metadata identifies Strata Critical Medical, Inc. and “2023 Q4,” which does not match the filing text; this summary therefore covers Blade’s full-year 2023 results, not a standalone fourth quarter.
Blade provides asset-light air transportation and medical logistics services through Passenger and Medical segments. Passenger services include short-distance helicopter and seaplane flights and jet charter; Medical services primarily transport human organs and supporting medical teams. Blade generally relies on third-party aircraft operators and uses proprietary booking, tracking and logistics technology.
Financial Performance and Liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $225.2 million | $146.1 million | Up 54% |
| Loss from operations | $(68.1) million | $(53.5) million | Loss increased |
| Net loss | $(56.1) million | $(27.3) million | Loss increased |
| Net loss per share | $(0.76) | $(0.38) | Loss per share increased |
| Net cash used in operating activities | $(32.3) million | $(37.1) million | Use decreased |
| Total flight profit | $42.1 million | $22.9 million | Up 84% |
| Total flight margin | 18.7% | 15.7% | Up 3.0 percentage points |
| Segment adjusted EBITDA | $5.8 million | $(1.3) million | Improved |
Revenue growth was led by Medical revenue of $126.6 million, up 76%, and Passenger revenue of $98.6 million, up 33%. Short Distance revenue increased 57% to $70.7 million, while Jet and Other revenue declined 5% to $27.9 million. Seats flown increased to 154,608 from 106,368.
Cost of revenue increased 48% to $183.1 million, but declined to 81% of revenue from 85%. Operating expenses increased to $293.3 million, or 130% of revenue, primarily reflecting growth-related expenses, a $20.8 million Blade Europe intangible impairment, higher personnel costs and a $3.4 million Trinity acquisition earn-out compensation expense.
At December 31, 2023, Blade had cash and cash equivalents of $27.9 million, short-term investments of $138.3 million and restricted cash of $1.1 million, for total liquidity of approximately $166.1 million. The company reported zero debt and net working capital of $170.8 million. Management stated that existing liquidity should fund current operations for at least the next 12 months, although the company expects short-term net losses.
Material Changes Versus 2022
- Revenue increased $79.1 million, primarily from higher Medical activity, new hospital clients, longer average medical trips and the inclusion of a full year of Blade Europe operations.
- Medical flight margin improved to 17.9% from 16.1%, supported by higher utilization of dedicated aircraft, increased revenue per flight hour and greater use of company-owned ground vehicles.
- Passenger flight margin improved to 19.7% from 15.2%, although the Passenger segment remained loss-making on a GAAP basis.
- Net loss more than doubled, despite revenue and flight-profit growth, principally because of the Blade Europe impairment and higher corporate and personnel costs.
- Blade discontinued its seasonal New York-to-South Florida by-the-seat jet service in the fourth quarter of 2023 and does not expect significant Jet and Other seasonality in 2024.
- Cash used in operations improved by $4.8 million, but cash, cash equivalents and restricted cash declined by $15.4 million during 2023.
- Approximately 46% of 2023 flight costs were subject to capacity purchase agreements containing minimum flight-volume guarantees.
Outlook, Commentary, Risks and Unusual Items
Management expects continued near-term net losses while pursuing growth in Passenger and Medical services. Blade believes it has sufficient liquidity for its current business plan over the next 12 months, but longer-term funding needs may depend on expansion, customer demand, capital expenditures and acquisitions. The filing does not provide formal revenue, earnings or cash-flow guidance.
Blade’s strategy depends partly on the future certification, availability, adoption and economics of electric vertical aircraft. No such aircraft were certified by the FAA for commercial operations in the United States as of the filing. Delays in commercialization of this technology contributed to the Blade Europe impairment and could result in further impairments if projected growth or margin improvements do not materialize.
- Management identified two material weaknesses in internal control over financial reporting: ineffective IT general controls over user access and change management, and deficiencies in the revenue process. Remediation was ongoing, with completion expected before the end of 2024; the weaknesses are not considered remediated until controls operate effectively for a sufficient period.
- Blade expects approximately $10.1 million of Trinity earn-out consideration for 2023 results, including approximately $7.1 million in cash, to be paid in the first quarter of 2024. This is the final year subject to the earn-out.
- As of December 31, 2023, minimum flight purchase guarantees were approximately $14.0 million for 2024 and $21.6 million for 2025, subject to specified cancellation and termination rights.
- On March 11, 2024, Blade agreed to acquire eight fixed-wing aircraft for approximately $21.0 million, funded with $9.3 million of existing prepaid deposits and approximately $11.7 million of cash. The aircraft are intended to support the Medical business and will continue to be operated by M&N.
- The company recognized $15.2 million of stock-based compensation in 2023 and had $24.2 million of unamortized restricted-stock compensation at year-end.
- Two putative class actions were filed in February 2024 relating to the prior acquisition of Blade and allege deficiencies in the merger proxy and related fiduciary-duty matters. The complaints seek damages, fees and costs; the filing does not provide a clear estimate of potential loss.
- The federal grand jury investigation into the transplant transportation industry was closed in August 2023, and Blade was released from obligations under the related subpoena.
- Key operating risks include aviation safety incidents, reliance on third-party operators, operator capacity and minimum guarantees, regulatory restrictions at airports and heliports, customer and geographic concentration, cybersecurity and privacy compliance, competition, fuel availability, weather, international integration and continued losses.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Blade Air Mobility, Inc., not Strata Critical Medical, Inc.
- Reconcile strong revenue and flight-margin growth with the continuing $56.1 million GAAP net loss and $32.3 million operating cash burn.
- Assess whether Blade Europe can achieve management’s projected operating improvements and whether additional intangible or goodwill impairment is possible.
- Monitor remediation of the two material weaknesses and any impact on the reliability or timeliness of future financial reporting.
- Evaluate liquidity after the $10.1 million Trinity earn-out and the approximately $21.0 million aircraft acquisition, including the $11.7 million cash component.
- Review the economics, termination rights and future cash obligations under capacity purchase agreements and aircraft leases.
- Verify the certification timeline and commercial economics of electric vertical aircraft, which are material assumptions in the company’s European valuations and strategy.
- Review the February 2024 litigation, the March 2024 aircraft purchase, executive equity grants and potential dilution from outstanding warrants, options, restricted stock and performance-based awards.